Products for Research Use Only
RegisterLogin

Talacotuzumab

CAT: 0804-HY-P99395-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99395-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) . Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models[1][2][3][4].
CAS Number
1826831-79-1
Product Name Alternative
JNJ 56022473; CSL 362
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/talacotuzumab.html
Purity
98.82
Solubility
H2O
Smiles
[Talacotuzumab]
Molecular Weight
(147.42 kDa)
References & Citations
[1]S J Busfield, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014 Nov;28 (11) :2213-21.|[2]Shereen Oon, et al. A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus. JCI Insight. 2016 May 5;1 (6) :e86131.|[3]Erwin M Lee, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015 Jul;100 (7) :914-26.|[4]L H Xie, et al. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission. Blood Cancer J. 2017 Jun 2;7 (6) :e567.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3

Alternative Products

CatalogName
GTR18153948-01Talacotuzumab
GTR18337893-01Talacotuzumab Antibody
T9901A-214-01Talacotuzumab MMAE
E100571Talacotuzumab ELISA Kit
DHD72501Research Grade Talacotuzumab
DHD72599Talacotuzumab-MMAE (ADC)
E55B0381Talacotuzumab (Reference antibody)
592227Talacotuzumab (CD123, IL3Ra)
GTR18578303-01Talacotuzumab MMAE Antibody
KBI1658KRIBIOLISA™ Talacotuzumab ELISA

Popular Products